EFFECTIVE pharmacological control of severe arterial hypertension has been available for more than a decade. A combination of an orally administered ganglioplegic agent and hydralazine was first found to induce sustained reduction of blood pressure to normal or nearly normal levels in the summer of 1951,1 and a practical therapeutic regimen was quickly developed.2 A large series of patients, selected only for severity of the hypertensive process, was treated with this regimen in order to evaluate its long-term effects on mortality and morbidity. Interim reports on various aspects of the study have been published.3-6 The present report concerns 316 patients suffering from moderately severe and severe hypertension who began to ingest ganglioplegic agents and hydralazine more than 7 years ago; almost half of them began more than 12 years ago. Therapy was intensive, as doses of drugs large enough to produce the desired antihypertensive effect were employed in every case. This report cites the mortality associated with differing severities of hypertensive disease. It examines the significance of advanced hypertensive retinopathy by comparing patients exhibiting this finding with those having other hypertensive complications. The time and cause of death are considered as
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Methods
Each of the 316 patients had a mean diastolic blood pressure of 110 mm Hg or more at rest in bed in the hospital prior to therapy. During the 6 years beginning in August 1951, each began to ingest a ganglioplegic agent and hydralazine as described,2 and each continued this intensive therapy under our supervision for more than 2 weeks. Only 12 other patients met these criteria; they could not be followed, and hence are excluded from the series. The 316 patients were almost equally divided between those with advanced hypertensive retinopathy and those without it. These two distinct populations were both subdivided into two relatively homogeneous groups: 162 patients with retinopathy were divided into those with azotemia and those without it, and 154 patients without retinopathy were divided into those with cardiovascular or renal complications and those without obvious changes resulting from hypertension.
The 154 patients without advanced retinopathy, and hence with so-called benign stages of hypertension, were divided on the basis of Smithwick's criteria7 into two groups which for the sake of brevity are designated in the tables and figures as "Benign Uncomplicated" and "Benign Complicated." There were 103 patients in the group without obvious complications ("Benign Uncomplicated"); according to usual diagnostic procedures none of them exhibited serious vascular involvement of brain, heart, or kidney, and all of them had mean diastolic blood pressures at bed rest of at least 110 but less than 140 mm Hg. Eighteen of these cases were classified in Circulation, Volume XXXIII, June 1966 Smithwick's group II and 85 in his group II. * There were 51 patients without advanced retinopathy but with serious vascular changes associated with hypertension ("Benign Complicated"): cerebral vascular accidents, congestive heart failure, impairment of renal function, or mean diastolic blood pressures at bed rest of 140 mm Hg or more. Although some of these patients initially exhibited hemorrhages or exudates, or both, in their ocular fundi, papilledema was absent, and for the purposes of this study they were not included in the groups with advanced retinopathy. Azotemia was not found in those without congestive failure, nor in those with it after their hearts had regained compensation. All 51 cases were classified in Smithwick's group IV.
Papilledema with hemorrhagic or exudative retinitis, or both, a mean diastolic blood pressure at bed rest of 120 mm Hg or more, proteinuria, and diminished renal function were found in 162 patients. Their maximal renal excretion of 6 mg of intravenously administered phenol red (P.S.P.) was 22% in 15 minutes despite an adequate volume of urine, and all but five of the 162 were unable to excrete more than 15% during this interval. These 162 patients, who were also classified in Smithwick's group IV, met the diagnostic criteria for the malignant or accelerated stages of hypertension.
In 97 cases, nonprotein nitrogen in plasma was 30 mg per 100 ml or less, measured after deproteinization by zinc hydroxide.t This group of 97 is designated as "Malignant Nonazotemic" in the tables and figures. In 65 cases, plasma nonprotein nitrogen was 31 to 116 mg per 100 ml. This latter group of 65, designated as "Malignant Azotemic," was considered to represent advanced stages of "malignant hypertension." The division of patients into groups, and the number in each, is summarized (diagram): The foregoing designations refer to the condition of the patient on the initial examination and in no way describe subsequent changes during therapy. Papilledema disappeared, hemorrhages were absorbed, and exudates regressed in every malignant hypertensive patient who continued effective treatment. Slightly or moderately elevated plasma nonprotein nitrogen often remained stable for long periods and occasionally diminished to nearly normal levels, as we have reported.4' 6 Without intent on our part, there was a change in the type of patient entering the series between 1951 and 1957. Initially many patients had apparently uncomplicated benign hypertension, but such individuals soon began to be treated elsewhere. Therefore, the proportion with malignant hypertension increased from 40% of the total during the first year to 80% during the last 3 years that patients entered the study (table 1), making the population considered here somewhat different from that previously reported.1-6 The average age of the 316 patients was 46.4 years. There *The four groups of treated patients are defined more precisely: The median age for both groups with malignant hypertension approximated 45 years; for the two groups with benign hypertension it was 49 years. The sex ratio was essentially the same for all groups, but the percentage of Negroes and ward (as opposed to private) patients increased with the severity of the disease. Only 5% of the groups with benign hypertension were Negro and 19% were ward patients; 20% of the group with malignant hypertension but no azotemia were Negro and 39% were ward patients; and finally, 41% of the group with malignant hypertension and azotemia were Negro and 65% were ward patients.
were 144 men, and 106 "ward" patients of whom 60 were Negro.* In the hospital, therapy with a ganglioplegic agentt and then with hydralazine was instituted, as described. 2 The aim of treatment in each case was diastolic normotension. Before leaving the hospital each patient was taught to measure and record his own blood pressure and to control it with variable doses of the ganglioplegic agent and an invariant dose of hydralazine. Initially both drugs were ingested every 4 or 5 hours except at night, with the intake of the former regulated by the systolic blood pressure of the seated patient immediately before each dose. In August 1964, 13 years after the series was begun, the blood pressure, antihypertensive regimen, and cardiovascular and renal status were evaluated for all living patients; for patients who had died, records of the blood pressure and the cause of death were obtained whenever possible. Results
The Group of 316 Patients
Of the 316 patients, 126 were alive in August 1964 and 190 were dead (table 1). The survival curves for the four groups of varyingly severe, but similarly treated, hypertensive patients differed markedly ( fig. 1 ). The 12-year survival rate of the 146 patients who began therapy before August 1952 ranged from 71% for the group with the least severe tThe ganglioplegic agents used included hexamethonium chloride, pentolinium bitartrate, chlorisondamine chloride, and mecamylamine hydrochloride. Later in the study guanethidine sulfate was also used. The first three columns indicate the numbers of patients who entered the series during the first year (mid-1951 to mid-1952), the next 2 years (mid-1952 to mid-1954) and the next 3 years of the study (mid-1954 to mid-1957). Per cent survival in August 1964 is indicated by the italicized figures following the totals for each group, and include well-treated, inadequately controlled, and uncooperative patients discontinuing therapy. The relative numbers of patients with malignant hypertension presenting themselves for treatment increased from 40% in the first year to more than 80% in the last 3 years during which patients entered the study.
(irculation, Volume XXXIII, June 1966 to zero for the group with the most advanced hypertension. Although the curve for the group with benign hypertension and vascular complications resembled the curve for the group with malignant hypertension but no azotemia, they were not identical. Initially the survival rate was higher among the former; it was approximately the same for both groups from 40 to 60 months after therapy was instituted; thereafter it was higher for the latter. After 12 years, 38% of the 39 patients with malignant hypertension but no azotemia were alive in contrast to 18% of the 28 patients with benign hypertension and vascular complications.
Records of the blood pressure, measured several times daily at home, were available for nearly all patients who were living 1 year after the institution of therapy. After 4 years, one in 10 of the patients with benign hypertension was no longer making frequent measurements; whereas measurements were continued by nearly all surviving patients with malignant hypertension. After 12 years, a fourth to a fifth of the groups with benign hypertension and an eighth of the group with malignant hypertension no longer continually monitored their blood pressures ( fig. 2 ). Figure 2 also indicates how many of the patients who measured their blood pressures frequently at home maintained adequate control of their hypertension. One year after therapy had been instituted and at least 4 hours after ingesting their last antihypertensive medication, the percentages of patients who, while seated, had average diastolic blood pressures less than 100 mm Hg ranged
The percentage of the surviving patients in each of the four groups defined in the text is indicated for every month from 1 to 144 after the inception of therapy. The number after the group designation indicates the number of patients originally in each group. 
BLOOD PRESSURE OF SURVIVING PATIENTS

Figure 2
The surviving patients in each of the four groups defined in the text are divided into three categories on the basis of whether they did not take their blood pressures at all, whether they took them occasionally, or whether they took them an average of at least twice daily. This division was made thrice: 1, 4, and 12 years after therapy begun. The group which monitored frequently was further divided into those with mean diastolic pressures less than 100 mm Hg and those with mean diastolic pressures greater than or equal to 100 mm Hg. The fraction at the top of each column tabulates the number of surviving patients over the number of patients in each of the four groups. Thus for the uncomplicated group, 102 of 103 were alive 1 year after therapy was instituted. from 78% for the group with least severe to 66% for the group with most advanced hypertension. After 4 years of therapy, the diastolic pressure averaged less than 100 mm Hg for approximately 80% of the surviving patients in all four groups. After 12 years, the surviving patients with malignant hypertension were better controlled than were those with benign hypertension.
Causes of Death of 142 Patients
Of the 190 patients known to have died before August 1964, the causes of death were relatively certain for 142. Of these, 80% died from five conditions: approximately one third from renal failure, nearly one sixth each from hemorrhagic stroke or myocardial infarction, and nearly one twelfth each from fibrinous pneumonitis associated with hexamethonium or from cancer (table 2). Three fifths of the 48 deaths from renal failure occurred in patients who were azotemic before therapy, 16 of them dying less than 1 year and nine of them more than 4 years after therapy was instituted. Fatal hemorrhagic strokes were concentrated in the second, third, and fourth years after treatment began, while fatal myocardial infarctions tended to occur later. The 73 deaths from renal failure, hemorrhagic stroke, and cardiac failure in the presence of high diastolic pressures were believed to be associated with hypertension. The 34 deaths from thrombotic stroke, myocardial infarction, and ruptured aortic aneurysms were considered to be associated with arteriosclerosis. Approximately 75% of the deaths from hypertension occurred among patients with malignant hypertension, and approximately 60% of the deaths from arteriosclerosis occurred among patients with benign hypertension (table 2) .
Causes of death were also analyzed with respect to how well a patient controlled his diastolic blood pressure (table 3) . For patients with benign hypertension, 11 of 17 deaths were of hypertensive origin when the mean diastolic pressure was uncontrolled and exceeded 120 mm Hg, whereas 16 of the 28 deaths were of arteriosclerotic causes when the mean diastolic pressure was controlled below 100 mm Hg. In particular, the eight hemorrhagic strokes and only three fatal thrombotic episodes among uncontrolled patients with benign hypertension contrast strikingly with the 12 fatal thrombotic episodes and only one hemorrhagic stroke, among controlled patients with similarly severe degrees of hypertension before therapy began.
The survival curves of the group with benign hypertension and vascular complications and of the group with malignant hypertension but no azotemia cross after 40 to 60 months of therapy ( fig. 1 ). In table 4, part 1 are shown the causes of death of the 18 patients from each of these two groups who began therapy more than 12 years ago, continued treatment and died with mean diastolic blood pressures of less than 110 mm Hg. Nine of the group with benign hypertension died of arteriosclerotic and only three of hypertensive complications, whereas nine of the group with malignant hypertension died of hypertensive and only two of arteriosclerotic complications. About a sixth of the patients in each of these two groups discontinued therapy with the prompt recrudescence of diastolic pressures greater than 120 mm Hg; every one of them died, with hypertensive complications responsible for all deaths of which the causes were known ( 
Pressures
Of the 126 patients known to be living in August 1964, 94 had mean diastolic pressures below 100 mm Hg, documented by several daily determinations. Table 5 indicates their present therapy. Nearly two fifths (39%) of these patients remain on a regimen similar to their initial one and continue to ingest both hydralazine and a ganglioplegic agent, sometimes augmented by a relatively impotent drug such as an oral diuretic or a Rauwolfia alkaloid. Nearly a third (32%) now use only one potent antihypertensive drug, again sometimes augmented by oral diuretics or Rauwolfia alkaloids. The remaining 27 patients (29%o) are most interesting. Their requirements for antihypertensive drugs have diminished gradually but markedly since therapy began. At the time of writing, 10 control their diastolic pressures with oral diuretics or Rauwolfia alkaloids alone. Seventeen ingest no antihypertensive drugs regularly, although four resort to an occasional dose of one of the relatively impotent drugs. Ten of the 27 had once had malignant hypertension.
Sixteen of the 316 patients had prolonged remissions of their hypertension; 15 were living in August 1964 and one had died after maintaining diastolic normotension without medication for almost 6 years (table 6). Two living patients from the first column of table 5 were excluded because apoplectic strokes may have conditioned their remissions. The pretreatment diastolic pressures of the 16 while in the hospital and their considerable intakes of antihypertensive medication at the onset of therapy attest to the severity of their hypertension at that time. The five with malignant hypertension were able to discontinue therapy an average of 64 months after its initiation; whereas the 11 with benign hypertension were able to discontinue therapy after an average of only 32 months. Interestingly enough, seven of the 16 patients had toxic manifestations caused by hydralazine and simulating colla- gen disease: in six instances toxicity was moderate and exposure to hydralazine continued for a total of more than a year after symptoms appeared. Several other living patients, whose intake of antihypertensive drugs had markedly decreased, were excluded from this table because of uncertainty about their diastolic pressures; they discontinued measuring their blood pressures before or at the time they discontinued drugs.
In 18 of the 126 living patients, cardiovascular or renal complications have developed since therapy was instituted (table 7). The incidence was highest among patients with benign hypertension who already had vascular complications prior to therapy, and in this group all new complications were arteriosclerotic. Six of the 18 had not maintained their diastolic pressures below 100 mm Hg.
Comment
The relative efficacies of the intensive chemotherapy described here and extensive lumbodorsal sympathectomy as performed by Smith-wick7 can be approximated by comparing the mortality rates associated with the two regimens. It should be emphasized, however, that our patients with malignant hypertension had more severe renal dysfunction than did Smithwick's patients. 8 For his groups II and III, with 76% in group II, Smithwick reported a 10-year mortality rate of 33%. For our benign hypertensive patients without complications, with only 19% classified in Smithwick's group II, the gross 7-to-13-year mortality rate was 31% (table 1). For his group IV (which included a few patients with severe retinopathy and diminished renal function), Smithwick's 10-year mortality rate was 73%; for our benign hypertensive patients with complications (but without retinopathy) the 7-to-13year mortality was 80%. Our patients with malignant hypertension but no azotemia had a 7-to-13-year mortality rate of 59%, which is lower than that usually found after splanchnicectomy. Since the combination of advanced retinopathy andazotemia is considered a contraindication to surgery, no comparison of survival rates in this instance is possible. These In August 1964, cardiovascular renal complications had occurred in 18 then living patients. No patient, alive at that time, had discontinued therapy and survived a significant vascular complication. Individual patients are indicated by their age (at onset of therapy), race, and sex. The figure following the dash shows the number of months after the institution of therapy when the complication occurred. The letter following the figure indicates whether a patient had controlled his diastolic pressure and had a mean level below 100 mm Hg (C), or whether it was only partially controlled with a mean between 100 and 110 mm Hg (P). One patient, 42 W, had both a thrombotic stroke and a myocardial infarct.
data indicate that intensive chemotherapy, as described,2 allows two of three patients in Smithwick's groups II and III, and two of five patients with malignant hypertension but no azotemia to survive 10 years. In terms of survival, chemotherapy offers no advantages over surgical therapy to patients with serious arteriosclerotic complications, but it can permit a 5-year survival for nearly one in four individuals with malignant hypertension which has progressed to azotemia.
One variable which adversely affected the mortality rate of this series is the inclusion of uncooperative patients who discontinued chemotherapy against our advice. For example, the 12-year survival rate of 28 patients with benign hypertension and vascular complications was 18%; excluision of those stopping therapy, all of whom died (five patients), increased it to 22%. Likewise, the 12-year survival rate of 39 patients with malignant Circulation, Volume XXXIII, June 1966 hypertension but no azotemia was 38% for the whole group, 45% for those continuing therapy, and zero for those discontinuing it. Since cooperation in therapy is ensured after surgery, a comparison with chemotherapy would further favor the latter if uncooperative patients had been excluded from our series.
The eventually lower mortality among treated patients with malignant hypertension but no azotemia compared with a group of similarly treated patients with benign hypertension and vascular complications was surprising. Malignant hypertensive patients did not die at a constant rate during the 12 years of therapy, as indicated in figure 1 . At first the rate was relatively high, most deaths being related to renal failure or other hypertensive complications. Subsequently the mortality rate decreased, perhaps partly because the hypertension, and hence its complications, were controlled and perhaps partly because many Renal insufficiency Cardiac failure vulnerable or uncooperative patients had succumbed. In contrast the mortality rate of the benign hypertensive patients was more constant during the 12 years of treatment. Most cardiovascular deaths among patients in this group with adequately controlled diastolic pressures were related to arteriosclerotic processes which presumably were initiated before treatment began and progressed despite it (table 3) . The 25% incidence of arteriosclerotic complications in living and nearly normotensive patients belonging to this group (table 7) emphasizes the prevalence of advanced vascular disease among them.
One of the most intriguing aspects of antihypertensive therapy involves the protean iatrogenic diseases associated with it. The predilection of serious iatrogenic disease for the most severely hypertensive patients has been reported.9 Fatal fibrinous pneumonitis following ingestion of hexamethonium was confined to patients with malignant hypertension; moreover, at the time toxic manifestations developed, nine of 10 patients were azotemic.10 This poorly understood syndrome only occurred during the first year that ganglionic blockade was used, but during this time it was responsible for eight of the 27 deaths among malignant hypertensive patients with azotemia (table 2) . It has not been observed in association with ganglioplegic agents other than hexamethonium.
Toxic manifestations to hydralazine simulating collagen disease were accompanied by normal or nearly normal diastolic blood pressures.1" When hydralazine was discontinued soon after the appearance of toxic symptoms, significant hypertension reappeared, often uncontrollable by other agents. In contrast, when hydralazine was continued for considerable periods despite toxic symptoms, normotension or near normotension sometimes persisted long after the drug was finally discontinued and long after the last toxic symptom had vanished. Seven of the 16 prolonged remissions of hypertension which are tabulated in table 6 occurred-among 44 patients with hydralazine toxicity. Since there were only nine similarly prolonged remissions among the other 272 patients, the incidence of remission was significantly higher among those with this unique form of toxicity (chi-square 11.7; P<0.001).
It is noteworthy that four of the six aortic aneurysms causing death were dissecting aneurysms. Although aortic aneurysms have been listed as arteriosclerotic complications, the relatively high incidence of dissection raises the question of iatrogenic disease. Beaven and Murphy12 have reported an increased frequency of dissection in association with ganglionic blockade.
The ratio of deaths from hypertensive causes to deaths from arteriosclerotic causes steadily increased with the severity of the initial hypertension from less than unity for the group with benign hypertension and no vascular complications to more than 10 for the group with malignant hypertension and azotemia (table 2). The frequency of particular arteriosclerotic complications was different in living and dead patients. In the living, thrombotic stroke was more than thrice as common as myocardial infarction (table 7) , while for the dead the frequencies were reversed (table 2), suggesting that for this population myocardial infarction was much more likely to be fatal than thrombotic stroke. Furthermore, these data suggest that, although intensive chemotherapy may be partly effective in preventing progression of the hypertensive process, it does not materially affect the arteriosclerotic process.
Whereas national mortality rates from hypertensive heart disease have declined by 41.7% in the total population and 45.8% in white males during the decade 1950-1960 and are declining further, rates for vascular diseases affecting the central nervous system have declined by only 10.1% and 6.2%, respectively, and those from arteriosclerotic heart disease have risen.13 These changes may reflect the widespread influence of the chemotherapy of hypertension during the decade and the lack of effective treatment of arteriosclerosis. The study reported -hereinwas initiated near the beginning of this decade and suggests^both the efficacy and the limits of effectiveness of Circulation, Volumie XXXlIl, June 1966 intensive chemotherapy of hypertensive disease.
Although the literature since 1950 is replete with reports on the treatment of hypertension with one or more drugs, we are unaware of other large, long-term studies of intensive chemotherapy with sustained diastolic normotension as the goal and with daily monitoring of the blood pressure to determine how closely this goal was approximated, except perhaps, that of Hood. He briefly reported results similar to those presented herein.14
Summary and Conclusions
Ganglioplegic agents and hydralazine in effective antihypertensive doses were given to 316 patients with mean resting diastolic blood pressures of 110 mm Hg or more, beginning in August 1951. In August 1964, 126 were living and 190 were dead. In 145 cases therapy had been initiated more than 12 years before; in 110 it had begun between 10 and 12 years before; and in 61 it had begun 7 to 10 years before. The patients were divided into four groups with increasingly severe disease: those with benign and apparently uncomplicated hypertension (103 cases), those with so-called benign hypertension and serious vascular complications (51 cases), those with malignant hypertension (papilledema) but no azotemia (97 cases) and those with malignant hypertension and azotemia (65 cases). The 7-to-13-year survival rate in the first group was 69%, in the second 20%, in the third 41%, and in the fourth 8%. Approximately 25% of the fourth group survived 5 years, although mortality was high during the first year of therapy.
Patients discontinuing therapy against advice suffered from recrudescent hypertension and its serious consequences, which were often fatal. Ninety-four of the 126 surviving patients controlled their mean diastolic pressures below 100 mm Hg. Of these, 17 gradually diminished and finally discontinued all regular antihypertensive drugs without compromising the control of their hypertension. Ten additional patients have been able to eliminate both ganglioplegic agents and hydralazine and have controlled their blood pressures at nor-Circulation, Volume XXXIII, June 1966 mal levels with oral diuretics or Rauwolfia alkaloids. Another 33 use either hydralazine or ganglioplegic agents alone, while 38 still require both drugs. Remissions have appeared after an average of 42 months of therapy and have lasted to the present, for a mean of 75 months. Remissions were not confined to less severe cases, but occurred in all groups. Toxic reactions to hydralazine antedated seven remissions.
With this form of therapy, patients with advanced retinopathy and clinical malignant hypertension which has not progressed to azotemia have a more prolonged survival than do those with severe hypertension and arteriosclerotic complications. Patients with malignant hypertension that has progressed to azotemia may live for several years. Regardless of the severity of the initial disease, when the diastolic blood pressure was controlled at or near normotensive levels, the hypertensive state regressed under effective therapy in 64% of survivors, to the point where less intensive treatment, or no treatment at all, was needed for its control.
Comments on a Trial An icy wind was sweeping over the rubble-heaps of Nuremberg when the trial began on December 9, 1946 . It enveloped all of us in thick clouds of dust. The cold was oppressive-and the atmosphere too remained oppressive....
If we, as physicians, propose to claim that unconditional trust of the halt and the sick is indispensable to our work, wve must not shun the full light of publicity, we must gloss over nothing. It is quite likely that some scientist or other who here sees his name mentioned in connection with the crimes that now stand revealed, even though but on their farthest outskirts, may now for the first time perceive the frightful linkage necessarily hidden from his view in the time of tyrannv. The editors are very far from seeking to exalt themselves self-righteously above even a single such man, nor do they seek to indict him in the eyes of his fellows. The years of disaster have enmeshed all of us in guilt deeply enough, as it is, and the task of the day is to find bridges that will lead us to deeper insight. Not indictment but enlightenment, not ostracism but the blazing of a new trail-a common path into the future that may, in all our misery, at least spare us from self-abasement-such is the purpose of this record.-ALEXANDER MITSCHERLICH and FRED MIELKE, translated by HEINZ NORDEN: Doctors of Infamy: The Story of the Nazi Medical Crimes. New York, Henry Schuman, 1949, p. 151.
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